Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams

In this on-demand webcast from a live webinar, Joyce O’Shaughnessy, MD, reviews the current data supporting the utilization of Ki67 testing in HR-positive/HER2-negative early breast cancer, including strategies to promote adherence to oral CDK4/6 inhibitors.

Joyce O'Shaughnessy, MD
Program Director Sara Tolaney, MD, MPH
Program Director Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 11, 2022 Expired: May 10, 2023